Related Experiment Video
Updated: Dec 18, 2025
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.7K
Prostate-specific membrane antigen expression in melanoma metastases
Hayden Snow1, Stephen Hazell2, Nicholas Francis3
1Department of Academic Surgery, Melanoma and Sarcoma, The Royal Marsden NHS Foundation Trust, London, UK.
Journal of Cutaneous Pathology
|June 13, 2020
Summary
Prostate-specific membrane antigen (PSMA) shows promise as a biomarker for melanoma. PSMA immunohistochemistry demonstrated excellent discriminatory power in melanoma metastases, suggesting potential for diagnostic imaging.
Area of Science:
- Oncology
- Immunohistochemistry
- Molecular Imaging
Background:
- Prostate-specific membrane antigen (PSMA) is a key biomarker in prostate cancer staging using 68Ga-PSMA-11 PET/CT.
- Unexpected detection of melanoma metastases during prostate cancer PSMA-PET/CT prompted this investigation.
Purpose of the Study:
- To evaluate the diagnostic potential of PSMA immunohistochemistry in melanoma metastases.
- To explore PSMA as a novel imaging biomarker for melanoma detection and characterization.
Main Methods:
- PSMA immunohistochemistry was performed on 41 stage III/IV melanoma specimens.
- Receiver operating characteristic (ROC) curve analysis was used to assess diagnostic accuracy.
- Western blot and multiplex immunofluorescence were employed for further validation.
Main Results:
- PSMA immunohistochemistry achieved an area under the ROC curve of 0.82, indicating excellent discriminatory power (sensitivity 82.9%, specificity 73.2%).
- PSMA staining was most intense in tumor neovasculature within melanoma metastases.
- Weak PSMA expression was also observed in melanocytes.
Conclusions:
- PSMA immunohistochemistry exhibits significant potential as a diagnostic biomarker for melanoma.
- Findings support further clinical research for PSMA's use as a PET/CT radiotracer and intraoperative marker in melanoma.
